GeneDx Research Demonstrates Medical Actionability of Exome and Genome Sequencing Results in Large Real-World Study of More Than 300,000 PatientsBusiness Wire • Tuesday
GeneDx Holdings Corp. (WGS) Tops Q3 Earnings and Revenue EstimatesZacks Investment Research • Tuesday
GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic TestingBusiness Wire • 11/05/26
Did GeneDx Holdings Corp. Insiders Breach their Fiduciary Duties to Shareholders?PRNewsWire • 10/27/26
GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026Business Wire • 10/23/26
GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease DiagnosisBusiness Wire • 10/20/26
GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026Business Wire • 10/19/26
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026Business Wire • 10/07/26
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric CareBusiness Wire • 10/02/26
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type CBusiness Wire • 09/09/26
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children'sBusiness Wire • 08/24/26
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?Zacks Investment Research • 08/19/26
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and EpilepsyBusiness Wire • 08/11/26